Alto Neuroscience, Inc. (ANRO)
NYSE: ANRO · Real-Time Price · USD
2.360
+0.280 (13.46%)
Apr 15, 2025, 4:00 PM EDT - Market closed
Alto Neuroscience Employees
Alto Neuroscience had 76 employees as of December 31, 2024.
Employees
76
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$808,303
Market Cap
63.89M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 76 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| HCA Healthcare | 316,000 |
| Thermo Fisher Scientific | 125,000 |
| Medtronic | 95,000 |
| AstraZeneca | 92,900 |
| Sanofi | 82,878 |
| Novartis AG | 75,883 |
| Becton, Dickinson and Company | 73,000 |
| GSK plc | 68,629 |
ANRO News
- 26 days ago - Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights - Business Wire
- 6 weeks ago - The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation - Accesswire
- 7 weeks ago - Alto Neuroscience to Participate in Upcoming Investor Conferences - Business Wire
- 2 months ago - Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker - Business Wire
- 2 months ago - Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial - Business Wire
- 2 months ago - The Schall Law Firm Invites Investors With Losses To Join An Investigation Into Alto Neuroscience, Inc. For Securities Fraud - Accesswire
- 2 months ago - The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Investigation Into Alto Neuroscience, Inc. - Accesswire
- 2 months ago - The Schall Law Firm Invites Investors With Losses To Join An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud - Accesswire